[{"id":"64862772-4e2d-4d09-a25e-0a3cd662c549","acronym":"AALL1621","url":"https://clinicaltrials.gov/study/NCT02981628","created_at":"2021-01-18T14:40:03.526Z","updated_at":"2025-02-25T15:10:29.659Z","phase":"Phase 2","brief_title":"Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02981628 - AALL1621","lead_sponsor":"Children's Oncology Group","biomarkers":" KMT2A • CD22","pipe":" | ","alterations":" MLL rearrangement • CD22 expression","tags":["KMT2A • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 06/19/2017","start_date":" 06/19/2017","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-13"},{"id":"33da474f-b112-4a34-ad2b-bf3aa8c54e06","acronym":"AALL1231","url":"https://clinicaltrials.gov/study/NCT02112916","created_at":"2021-01-18T09:46:35.591Z","updated_at":"2025-02-25T16:51:23.270Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT02112916 - AALL1231","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO","pipe":" | ","alterations":" CD22 expression","tags":["CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 847","initiation":"Initiation: 10/04/2014","start_date":" 10/04/2014","primary_txt":" Primary completion: 03/31/2020","primary_completion_date":" 03/31/2020","study_txt":" Completion: 09/18/2025","study_completion_date":" 09/18/2025","last_update_posted":"2025-02-04"},{"id":"a5f14953-ab61-4581-b513-a86ad8a1e2b8","acronym":"AALL0434","url":"https://clinicaltrials.gov/study/NCT00408005","created_at":"2021-01-17T17:29:32.376Z","updated_at":"2025-02-25T16:50:52.092Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT00408005 - AALL0434","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO","pipe":" | ","alterations":" CD22 expression","tags":["CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • nelarabine • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1895","initiation":"Initiation: 01/22/2007","start_date":" 01/22/2007","primary_txt":" Primary completion: 09/30/2017","primary_completion_date":" 09/30/2017","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-04"},{"id":"62765188-4060-4462-ba62-f845b4a31a33","acronym":"","url":"https://clinicaltrials.gov/study/NCT05442515","created_at":"2022-07-05T14:54:21.934Z","updated_at":"2024-07-02T16:34:25.864Z","phase":"Phase 1/2","brief_title":"CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies","source_id_and_acronym":"NCT05442515","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD19 • CD22","pipe":" | ","alterations":" CD19 expression • CD22 expression","tags":["CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 12/28/2022","start_date":" 12/28/2022","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2029","study_completion_date":" 07/01/2029","last_update_posted":"2024-06-14"},{"id":"4b1e2885-ae3f-433a-8a0a-828ebea2022b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03448393","created_at":"2021-01-18T17:00:10.946Z","updated_at":"2024-07-02T16:34:37.765Z","phase":"Phase 1","brief_title":"CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies","source_id_and_acronym":"NCT03448393","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD19 • CD22","pipe":" | ","alterations":" CD19 expression • CD22 expression","tags":["CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/26/2018","start_date":" 03/26/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/31/2040","study_completion_date":" 12/31/2040","last_update_posted":"2024-06-06"},{"id":"1c9f6138-8d9a-47fc-a239-63c21b0bb4fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04815356","created_at":"2021-03-25T12:52:31.393Z","updated_at":"2024-07-02T16:34:38.088Z","phase":"Phase 1","brief_title":"Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant","source_id_and_acronym":"NCT04815356","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • JCAR018 • anti-CD22 CAR T"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 05/23/2022","start_date":" 05/23/2022","primary_txt":" Primary completion: 12/01/2036","primary_completion_date":" 12/01/2036","study_txt":" Completion: 12/01/2036","study_completion_date":" 12/01/2036","last_update_posted":"2024-06-05"},{"id":"dab15a96-876b-4fdc-b04d-c6d8c5e516df","acronym":"","url":"https://clinicaltrials.gov/study/NCT02315612","created_at":"2021-01-18T10:58:15.939Z","updated_at":"2024-07-02T16:34:58.824Z","phase":"Phase 1","brief_title":"Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies","source_id_and_acronym":"NCT02315612","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JCAR018 • anti-CD22 CAR T"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 123","initiation":"Initiation: 12/12/2014","start_date":" 12/12/2014","primary_txt":" Primary completion: 04/03/2019","primary_completion_date":" 04/03/2019","study_txt":" Completion: 06/01/2040","study_completion_date":" 06/01/2040","last_update_posted":"2024-06-05"},{"id":"ee6449ac-5095-4fbb-b724-e910caded562","acronym":"","url":"https://clinicaltrials.gov/study/NCT03620058","created_at":"2021-01-18T17:47:19.570Z","updated_at":"2024-07-02T16:35:00.949Z","phase":"Phase 1","brief_title":"CART22 Alone or in Combination With huCART19 for ALL","source_id_and_acronym":"NCT03620058","lead_sponsor":"University of Pennsylvania","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CART22 • huCART19"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 09/27/2018","start_date":" 09/27/2018","primary_txt":" Primary completion: 01/01/2036","primary_completion_date":" 01/01/2036","study_txt":" Completion: 01/01/2036","study_completion_date":" 01/01/2036","last_update_posted":"2024-05-24"},{"id":"c0cd590d-13ce-4ae0-8ee5-2117a8d7e3c4","acronym":"NCI-2018-02016","url":"https://clinicaltrials.gov/study/NCT03698552","created_at":"2021-01-18T18:07:38.337Z","updated_at":"2024-07-02T16:35:03.675Z","phase":"Phase 1/2","brief_title":"ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03698552 - NCI-2018-02016","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e epratuzumab-cys-tesirine (ADCT-602)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 08/24/2018","start_date":" 08/24/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-15"},{"id":"05e37930-8cbd-43e9-89a2-63149b04e396","acronym":"","url":"https://clinicaltrials.gov/study/NCT03913559","created_at":"2021-01-18T19:15:34.393Z","updated_at":"2024-07-02T16:35:08.745Z","phase":"Phase 2","brief_title":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","source_id_and_acronym":"NCT03913559","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • methotrexate • Besponsa (inotuzumab ozogamicin) • methylprednisolone sodium succinate"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 05/14/2019","start_date":" 05/14/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-04-19"},{"id":"d0063cdd-ab4b-4009-8105-73c4b7241cf5","acronym":"IRB-50836","url":"https://clinicaltrials.gov/study/NCT04088890","created_at":"2021-01-18T20:00:46.615Z","updated_at":"2024-07-02T16:35:15.877Z","phase":"Phase 1","brief_title":"Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies","source_id_and_acronym":"NCT04088890 - IRB-50836","lead_sponsor":"Stanford University","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive • CD22 expression • CD20 negative","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive • CD22 expression • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • firicabtagene autoleucel (CRG-022)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/12/2019","start_date":" 09/12/2019","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2037","study_completion_date":" 12/30/2037","last_update_posted":"2024-03-07"},{"id":"b244d21b-7ca6-459d-808a-603983ee64ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03233854","created_at":"2021-01-18T15:58:49.473Z","updated_at":"2024-07-02T16:35:17.505Z","phase":"Phase 1","brief_title":"CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies","source_id_and_acronym":"NCT03233854","lead_sponsor":"Crystal Mackall, MD","biomarkers":" CD19 • CD22","pipe":" | ","alterations":" CD19 positive • CD19 expression • CD22 expression","tags":["CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD19 expression • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • avipendekin pegol (NKTR-255) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 09/01/2017","start_date":" 09/01/2017","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2035","study_completion_date":" 09/01/2035","last_update_posted":"2024-02-28"},{"id":"b2fd0720-c684-4f4d-8475-75c34a4514c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04088864","created_at":"2021-01-18T20:00:46.042Z","updated_at":"2024-07-02T16:35:19.768Z","phase":"Phase 1","brief_title":"CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies","source_id_and_acronym":"NCT04088864","lead_sponsor":"Stanford University","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive • CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • firicabtagene autoleucel (CRG-022)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 09/10/2036","study_completion_date":" 09/10/2036","last_update_posted":"2024-02-12"},{"id":"b5433020-6fcb-49f0-a449-5146dab9a586","acronym":"IntReALL SR 2010","url":"https://clinicaltrials.gov/study/NCT01802814","created_at":"2021-01-18T07:59:00.034Z","updated_at":"2024-07-02T16:35:19.923Z","phase":"Phase 3","brief_title":"International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010","source_id_and_acronym":"NCT01802814 - IntReALL SR 2010","lead_sponsor":"Charite University, Berlin, Germany","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Epratucyn (epratuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 700","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 07/31/2023","primary_completion_date":" 07/31/2023","study_txt":" Completion: 07/31/2023","study_completion_date":" 07/31/2023","last_update_posted":"2024-02-09"},{"id":"333c3c91-e311-42ae-a48a-8af632ca1e7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02650414","created_at":"2021-01-18T12:54:06.464Z","updated_at":"2024-07-02T16:35:20.907Z","phase":"Phase 1","brief_title":"CD22 Redirected Autologous T Cells for ALL","source_id_and_acronym":"NCT02650414","lead_sponsor":"University of Pennsylvania","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CART22"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/13/2016","start_date":" 01/13/2016","primary_txt":" Primary completion: 12/01/2037","primary_completion_date":" 12/01/2037","study_txt":" Completion: 12/01/2037","study_completion_date":" 12/01/2037","last_update_posted":"2024-02-05"},{"id":"02b59dda-a0bd-4079-9e1d-c7572a4affab","acronym":"","url":"https://clinicaltrials.gov/study/NCT05010564","created_at":"2021-08-18T14:53:29.281Z","updated_at":"2024-07-02T16:35:21.048Z","phase":"Phase 1","brief_title":"Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)","source_id_and_acronym":"NCT05010564","lead_sponsor":"Baylor College of Medicine","biomarkers":" CD20 • CD19 • CD22","pipe":" | ","alterations":" CD19 expression • CD22 expression","tags":["CD20 • CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • autologous TriCAR T • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 07/18/2023","start_date":" 07/18/2023","primary_txt":" Primary completion: 07/17/2026","primary_completion_date":" 07/17/2026","study_txt":" Completion: 03/29/2040","study_completion_date":" 03/29/2040","last_update_posted":"2024-02-02"},{"id":"70500982-fdb6-4f26-bc62-15198d012f0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05674175","created_at":"2023-01-06T15:58:48.048Z","updated_at":"2024-07-02T16:35:25.792Z","phase":"Phase 1/2","brief_title":"Co-administration of CART22-65s and huCART19 for B-ALL","source_id_and_acronym":"NCT05674175","lead_sponsor":"Stephan Grupp MD PhD","biomarkers":" CD22","pipe":" | ","alterations":" CD19 expression • CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T) • CART22 • huCART19"],"overall_status":"Recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 01/25/2023","start_date":" 01/25/2023","primary_txt":" Primary completion: 01/15/2027","primary_completion_date":" 01/15/2027","study_txt":" Completion: 01/15/2029","study_completion_date":" 01/15/2029","last_update_posted":"2023-12-19"},{"id":"c6d4f78d-e9fb-44fb-b084-86b60a1d4509","acronym":"","url":"https://clinicaltrials.gov/study/NCT06087419","created_at":"2023-10-17T15:12:56.219Z","updated_at":"2024-07-02T16:35:30.632Z","phase":"Phase 1/2","brief_title":"A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients","source_id_and_acronym":"NCT06087419","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Besponsa (inotuzumab ozogamicin) • Epidaza (chidamide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 10/30/2023","start_date":" 10/30/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-11-02"},{"id":"88bb823f-8d19-42f2-88d3-d87f1401dab8","acronym":"BALLI-01","url":"https://clinicaltrials.gov/study/NCT04150497","created_at":"2021-01-18T20:14:43.892Z","updated_at":"2024-07-02T16:35:35.864Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)","source_id_and_acronym":"NCT04150497 - BALLI-01","lead_sponsor":"Cellectis S.A.","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • lasmecabtagene timgedleucel (UCART22)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 10/14/2019","start_date":" 10/14/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2023-09-25"},{"id":"814e7ac6-45cf-46b6-b5f8-c3e997f1b25c","acronym":"EWALL-INO","url":"https://clinicaltrials.gov/study/NCT03249870","created_at":"2021-01-18T16:03:23.303Z","updated_at":"2024-07-02T16:35:38.086Z","phase":"Phase 2","brief_title":"Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL","source_id_and_acronym":"NCT03249870 - EWALL-INO","lead_sponsor":"Versailles Hospital","biomarkers":" ABL1 • BCR • CD22","pipe":" | ","alterations":" CD22 expression","tags":["ABL1 • BCR • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 12/28/2017","start_date":" 12/28/2017","primary_txt":" Primary completion: 05/30/2023","primary_completion_date":" 05/30/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-09-06"},{"id":"34cdff59-a647-4371-a823-819a079db705","acronym":"","url":"https://clinicaltrials.gov/study/NCT04747912","created_at":"2021-02-10T14:56:01.167Z","updated_at":"2024-07-02T16:35:39.011Z","phase":"Phase 2","brief_title":"Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)","source_id_and_acronym":"NCT04747912","lead_sponsor":"University of Chicago","biomarkers":" ABL1 • BCR • CD22","pipe":" | ","alterations":" CD22 expression","tags":["ABL1 • BCR • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Iclusig (ponatinib) • Besponsa (inotuzumab ozogamicin) • vincristine"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/02/2021","start_date":" 03/02/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-08-25"},{"id":"67a1b566-5352-4456-a3e7-7e3b946bf5d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04340154","created_at":"2021-01-18T21:00:26.726Z","updated_at":"2024-07-02T16:35:41.174Z","phase":"Phase 2","brief_title":"Study of Sequential CAR-T Cell Treating Leukemia Children","source_id_and_acronym":"NCT04340154","lead_sponsor":"Beijing Boren Hospital","biomarkers":" ABL1 • CD22","pipe":" | ","alterations":" CD19 expression • CD22 positive • CD22 expression","tags":["ABL1 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 positive • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/01/2020","start_date":" 05/01/2020","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-08-02"},{"id":"bb237587-56bb-4728-a5f6-2bd9743a439d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03991884","created_at":"2021-01-18T19:37:32.714Z","updated_at":"2024-07-02T16:35:43.756Z","phase":"Phase 1","brief_title":"Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03991884","lead_sponsor":"University of Washington","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive • CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • daunorubicin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 09/24/2019","start_date":" 09/24/2019","primary_txt":" Primary completion: 10/20/2022","primary_completion_date":" 10/20/2022","study_txt":" Completion: 06/28/2023","study_completion_date":" 06/28/2023","last_update_posted":"2023-07-06"},{"id":"074dadc5-1353-4b92-b222-659e5cb7d757","acronym":"","url":"https://clinicaltrials.gov/study/NCT04648475","created_at":"2021-01-19T20:40:05.443Z","updated_at":"2024-07-02T16:35:50.308Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma","source_id_and_acronym":"NCT04648475","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6 • CD22 • IL10","pipe":" | ","alterations":" CD19 expression • CD22 positive • CD22 expression • IL10 elevation","tags":["IL6 • CD22 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 positive • CD22 expression • IL10 elevation"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/25/2020","start_date":" 08/25/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"}]